Correction. Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder: Findings From a 12-Month Open-Label Study

In the article “Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder: Findings From a 12-Month Open-Label Study” by Maurizio Fava, MD; Luca Pani, MD; Sara De Martin, PhD; Andrew J. Cutler, MD; Charles W. Gorodetzky, MD, PhD; Frank J. Vocci, PhD; Frank L. Sapienza, MS; Thomas R. Kosten, MD; Cornelia Kröger, PhD; Paggard Champasa, PhD; Clotilde Guidetti, MD; Stefano Comai, PhD; Andrea Mattarei, PhD; Franco Folli, MD; David Bushnell, MS; Sergio Traversa, PharmD; Charles E. Inturrisi, PhD; Paolo L. Manfredi, MD; and Marco Pappagallo, MD, published in the March 2025 issue (J Clin Psychiatry 2025;86[1]:24m15438), the Relevant Financial Relationships section has been corrected to reflect relationships beyond those related to the article sponsor. The additional information is as follows: Dr Fava’s complete list of disclosures can be viewed at: https://mghcme.org/maurizio-fava-bio-disclosure/. Dr Pani has been a consultant for AbbVie, Acumen, Aicure, Alexion, BCG, Astra-Zeneca, Boehringer Ingelheim International GmbH, EDRA-LSWR Publishing Company, GH-Pharma, GLG-Institute, Immunogen, Johnson & Johnson, LB-Pharmaceuticals, Lundbeck, Magdalena BioSciences, MSD, NapoPharma, NetraMark, Pfizer Global, RAIN Scientific, Relmada Therapeutics, and Takeda and has shares/options in Relmada, NetraMark, and RAIN Scientific. Dr De Martin received fees from Aesculapius Farmaceutici for sponsored lectures. Dr Cutler has been a consultant and/or advisory board member for AbbVie, Acadia, Actinogen, Alfasigma, Alkermes, Anavex Life Sciences, Arrivo BioVentures, Autobahn Therapeutics, Axsome, Biogen, Biohaven,  Boehringer Ingelheim, Bristol Myers Squibb, Cognitive Research Corporation, Collegium Pharmaceutical, Corium, Delpor, Evolution Research Group, 4M Therapeutics, Intra-Cellular Therapies, J&J Innovative Medicine, Jazz Pharma, Knight Therapeutics, LivoNova, Lundbeck, Luye Pharma, MapLight Therapeutics, MedAvante-ProPhase, Mentavi, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, PaxMedica, Relmada, Sage Therapeutics, Sirtsei Pharmaceuticals, Supernus, Teva, Thynk, Tris Pharma, Vanda Pharmaceuticals, and VistaGen; has been on the speaker bureaus of AbbVie, Alfasigma, Alkermes, Axsome, Boehringer Ingelheim, Bristol Myers Squibb, Collegium Pharmaceutical, Corium, Intra-Cellular Therapies, J&J Innovative Medicine, Lundbeck, Neurocrine, Noven, Otsuka, Supernus, Teva, Tris Pharma, and Vanda Pharmaceuticals; and has stock options/equity in 4M Therapeutics. In the past 2 years, Dr Sapienza has consulted with 20 companies, focusing primarily on drug scheduling and supply chain issues for controlled substances; none of the consulting directly applied to clinical trial design or implementation.

Published Online: May 2, 2025. 
DOI: 10.4088/JCP.25lcx15938
J Clin Psychiatry 2025;86(2):25lcx15938